No teen on Bristol Myers Squibb’s heart drug had heart-pumping function fall below 50% in 56 weeks
Bristol Myers Squibb's Camzyos showed consistent efficacy and safety in a 56-week Phase 3 trial for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). No patient had left ventricular ejection fraction fall below 50%. The trial included a 28-week placebo-controlled period and demonstrated significant reductions in Valsalva left ventricular outflow tract gradient. Additional data will be presented at the American Heart Association’s Scientific Sessions 2026.
How this was made
The 30-second read
Why it matters
The new element is the 56-week follow-up framing for pediatric patients, plus references to additional adult evidence analyses to be presented at AHA Scientific Sessions 2026.
Market read
Investors get incremental clinical confidence for Camzyos in pediatrics, which can influence perceived risk and adoption trajectory, though it is not a new approval or financial update.
What to watch
The article emphasizes efficacy/safety endpoints but does not quantify commercial impact, dosing/monitoring burden, or any changes to REMS requirements that could affect real-world adoption and margins.
Background
The piece summarizes Phase 3 SCOUT-HCM results for Camzyos (mavacamten) in pediatric patients with symptomatic oHCM, including a 28-week placebo-controlled period and follow-up to week 56.
Ticker impact
Bristol Myers Squibb says its Camzyos Phase 3 SCOUT-HCM 56-week follow-up showed no pediatric patients had LVEF below the trial threshold and no new safety signals.
Likely modest upward bias as investors price in stronger durability of pediatric evidence and lower safety overhang.
The article provides specific trial follow-up outcomes (56-week duration, no LVEF deterioration below threshold, low TEAEs) but does not include new regulatory action or financial guidance.
Market effects
Reinforces the cardiac myosin inhibitor class evidence base in hypertrophic cardiomyopathy, potentially supporting broader investor appetite for CMI-related development.
Primarily US-focused sentiment via AHA Scientific Sessions-related disclosure; limited direct regional read-through.
International trial follow-up and multi-year adult evidence may strengthen global prescribing confidence for Camzyos.
Counterpoint
The pediatric dataset is small (44 randomized), so the absence of LVEF below threshold may not fully eliminate longer-term or broader-population safety uncertainty.
Key entities
- companyBristol Myers Squibb
Sponsor of Camzyos and presenter of SCOUT-HCM 56-week pediatric follow-up results.
- drugCamzyos (mavacamten)
Cardiac myosin inhibitor discussed for pediatric and adult oHCM efficacy and safety.
- clinical_trialSCOUT-HCM
Phase 3 randomized, double-blind, placebo-controlled pediatric trial with follow-up through week 56.
